Iovance Biotherapeutics, Inc.
IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candiā¦ read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.14
Price-3.44%
-$0.29
1Y
Price
Market Cap
$3.635b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-39.5%
EBITDA Margin-47.6%
Net Profit Margin-66.7%
Free Cash Flow Margin-39.5%
EBITDA Margin-47.6%
Net Profit Margin-66.7%
Free Cash Flow MarginRevenue
$324.969m
+23.3%
1y CAGR+4594.3%
3y CAGR+3445.7%
5y CAGREarnings
-$289.517m
+26.0%
1y CAGR+12.4%
3y CAGR+6.2%
5y CAGREPS
-$0.70
+35.8%
1y CAGR+27.6%
3y CAGR+26.8%
5y CAGRBook Value
$736.045m
$915.531m
Assets$179.486m
Liabilities$46.003m
DebtDebt to Assets
5.0%
-0.2x
Debt to EBITDAFree Cash Flow
-$296.395m
+11.9%
1y CAGR+8.2%
3y CAGR+0.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company